A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen
- PMID: 11739371
- DOI: 10.1074/jbc.C100686200
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen
Abstract
Lafora disease (progressive myoclonus epilepsy of Lafora type) is an autosomal recessive neurodegenerative disorder resulting from defects in the EPM2A gene. EPM2A encodes a 331-amino acid protein containing a carboxyl-terminal phosphatase catalytic domain. We demonstrate that the EPM2A gene product also contains an amino-terminal carbohydrate binding domain (CBD) and that the CBD is critical for association with glycogen both in vitro and in vivo. The CBD domain localizes the phosphatase to specific subcellular compartments that correspond to the expression pattern of glycogen processing enzyme, glycogen synthase. Mutations in the CBD result in mis-localization of the phosphatase and thereby suggest that the CBD targets laforin to intracellular glycogen particles where it is likely to function. Thus naturally occurring mutations within the CBD of laforin likely result in progressive myoclonus epilepsy due to mis-localization of phosphatase expression.
Similar articles
-
Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.Hum Mol Genet. 2003 Dec 1;12(23):3161-71. doi: 10.1093/hmg/ddg340. Epub 2003 Oct 7. Hum Mol Genet. 2003. PMID: 14532330
-
Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.Biochimie. 2006 Dec;88(12):1961-71. doi: 10.1016/j.biochi.2006.08.002. Epub 2006 Sep 14. Biochimie. 2006. PMID: 17010495
-
The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.Biochem Biophys Res Commun. 2004 Jan 23;313(4):1101-9. doi: 10.1016/j.bbrc.2003.12.043. Biochem Biophys Res Commun. 2004. PMID: 14706656
-
Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):99-107. doi: 10.2174/187221412800604617. Recent Pat Endocr Metab Immune Drug Discov. 2012. PMID: 22369717 Review.
-
Lafora disease offers a unique window into neuronal glycogen metabolism.J Biol Chem. 2018 May 11;293(19):7117-7125. doi: 10.1074/jbc.R117.803064. Epub 2018 Feb 26. J Biol Chem. 2018. PMID: 29483193 Free PMC article. Review.
Cited by
-
Advances in lafora progressive myoclonus epilepsy.Curr Neurol Neurosci Rep. 2007 Sep;7(5):428-33. doi: 10.1007/s11910-007-0066-7. Curr Neurol Neurosci Rep. 2007. PMID: 17764634 Review.
-
A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease.Genes Dev. 2007 Oct 1;21(19):2399-409. doi: 10.1101/gad.1553207. Genes Dev. 2007. PMID: 17908927 Free PMC article.
-
Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.Mol Neurobiol. 2017 Jul;54(5):3119-3130. doi: 10.1007/s12035-016-9884-4. Epub 2016 Apr 4. Mol Neurobiol. 2017. PMID: 27041370 Free PMC article.
-
Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research.Front Pharmacol. 2015 Jan 10;6:20. doi: 10.3389/fphar.2015.00020. eCollection 2015. Front Pharmacol. 2015. PMID: 25713537 Free PMC article. Review.
-
MRI characteristics due to gene mutations in a Chinese pedigree with Lafora disease.Mol Genet Genomic Med. 2023 Oct;11(10):e2228. doi: 10.1002/mgg3.2228. Epub 2023 Jul 17. Mol Genet Genomic Med. 2023. PMID: 37455597 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
